HUWE1 sirna

HUWE1 siRNA (Human)

Cat. Num. AAA8239468

• Gene Names: HUWE1; MULE; Ib772; LASU1; UREB1; HECTH9; URE-B1; ARF-BP1; HSPC272
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: HUWE1; HUWE1 siRNA (Human); KIAA0312; KIAA1578; UREB1; E3 ubiquitin-protein ligase HUWE1; ARF-binding protein 1; ARF-BP1; HECT. UBA and WWE domain-containing protein 1; Homologous to E6AP carboxyl terminus homologous protein 9; HectH9; Large structure of UREB1; LASU1; Mcl-1 ubiquitin ligase E3; Mule; Upstream regulatory element-binding protein 1; URE-B1; URE-binding protein 1; HUWE1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: HUWE1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 4374

• Applicable Applications for HUWE1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human HUWE1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for HUWE1 sirna

siRNA to inhibit HUWE1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 61676188
• NCBI GeneID: 10075
• NCBI Accession #: NP_113584.3
• NCBI GenBank Nucleotide #: NM_031407.6
• UniProt Accession #: Q7Z6Z7; O15029; Q4G2Z2; Q5H961; Q6P4D0; Q8NG67; Q9BUI0; Q9HCJ4; Q9NSL6; Q9P0A9
• Molecular Weight: 481,018 Da
• NCBI Official Full Name: E3 ubiquitin-protein ligase HUWE1
• NCBI Official Synonym Full Names: HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase
• NCBI Official Symbol: HUWE1
• NCBI Official Synonym Symbols: MULE; Ib772; LASU1; UREB1; HECTH9; URE-B1; ARF-BP1; HSPC272
• NCBI Protein Information: E3 ubiquitin-protein ligase HUWE1
• UniProt Protein Name: E3 ubiquitin-protein ligase HUWE1
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: HUWE1
• UniProt Synonym Gene Names: KIAA0312; KIAA1578; UREB1; ARF-BP1; HectH9; LASU1; Mule; URE-B1; URE-binding protein 1
• UniProt Entry Name: HUWE1_HUMAN

NCBI Description

This gene encodes a protein containing a C-terminal HECT (E6AP type E3 ubiquitin protein ligase) domain that functions as an E3 ubiquitin ligase. The encoded protein is required for the ubiquitination and subsequent degradation of the anti-apoptotic protein Mcl1 (myeloid cell leukemia sequence 1 (BCL2-related)). This protein also ubiquitinates the p53 tumor suppressor, core histones, and DNA polymerase beta. Mutations in this gene are associated with Turner type X-linked syndromic mental retardation. [provided by RefSeq, Aug 2013]

Uniprot Description

HUWE1: E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1. Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair. Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4. Binds to an upstream initiator-like sequence in the preprodynorphin gene. Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN. May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation. Interacts with isoform p14ARF of CDKN2A which strongly inhibits HUWE1 ubiquitin ligase activity. Interacts with MYCN, POLB and CDC6. Weakly expressed in heart, brain and placenta but not in other tissues. Expressed in a number of cell lines, predominantly in those from colorectal carcinomas. Belongs to the TOM1/PTR1 family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Ubiquitin conjugating system; Ubiquitin ligase; EC 6.3.2.-; Ligase; EC 6.3.2.19

Chromosomal Location of Human Ortholog: Xp11.22

Cellular Component: nucleoplasm; membrane; cytoplasm; nucleus

Molecular Function: protein binding; DNA binding; ubiquitin-protein ligase activity; ligase activity

Biological Process: protein monoubiquitination; protein polyubiquitination; base-excision repair; histone ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; cell differentiation

Disease: Mental Retardation, X-linked, Syndromic, Turner Type